Differential regulation of allergic airway inflammation by acetylcholine
File(s)Roberts et al. Frontiers in Immunology accepted.pdf (1.9 MB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Acetylcholine (ACh) from neuronal and non-neuronal sources plays important roles in the regulation of immune responses and is associated with the development of several disease pathologies. We have previously demonstrated that group 2 innate lymphoid cell (ILC2)-derived ACh is required for optimal type 2 responses to parasitic infection, and therefore sought to determine whether this also plays a role in allergic inflammation. RoraCre+ChatLoxP mice (in which ILC2s cannot synthesize ACh) were exposed to an allergenic extract of the fungus Alternaria alternata, and immune responses in the airways and lung tissues analysed. Airway neutrophilia and expression of the neutrophil chemoattractants CXCL1 and CXCL2 were enhanced 24 hours after exposure, suggesting that ILC2-derived ACh plays a role in limiting excessive pulmonary neutrophilic inflammation. The effect of non-selective depletion of ACh was examined by intranasal administration of a stable parasite-secreted acetylcholinesterase. Depletion of airway ACh in this manner resulted in more profound enhancement of neutrophilia and chemokine expression, suggesting multiple cellular sources for release of ACh. In contrast, depletion of ACh inhibited Alternaria-induced activation of ILC2s, suppressing expression of IL-5, IL-13 and subsequent eosinophilia. Depletion of ACh resulted in a reduction of macrophages with an alternatively activated M2 phenotype, and an increase in M1 macrophage marker expression. These data suggest that ACh regulates allergic airway inflammation in several ways, enhancing ILC2-driven eosinophilia, but suppressing neutrophilia through reduced chemokine expression.
Date Acceptance
2022-05-03
Citation
Frontiers in Immunology, 13
ISSN
1664-3224
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Immunology
Volume
13
Copyright Statement
Copyright © 2022 Roberts, Berkachy, Wane, Patel, Schnoeller, Lord, Gounaris, Ryffel,
Quesniaux, Darby, Horsnell and Selkirk. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Quesniaux, Darby, Horsnell and Selkirk. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
License URL
Sponsor
Wellcome Trust
Biotechnology and Biological Sciences Research Council (BBSRC)
Identifier
https://www.frontiersin.org/articles/10.3389/fimmu.2022.893844/full
Grant Number
097011/Z/11/Z
BB/R015856/1
Subjects
ILC2
acetylcholine
alternaria
chemokine
eosinophil
inflammation
lung
neutrophil
Acetylcholine
Acetylcholinesterase
Animals
Eosinophilia
Immunity, Innate
Inflammation
Interleukin-33
Lung
Lymphocytes
Mice
Pneumonia
Lung
Lymphocytes
Animals
Mice
Pneumonia
Eosinophilia
Inflammation
Acetylcholine
Acetylcholinesterase
Immunity, Innate
Interleukin-33
1107 Immunology
1108 Medical Microbiology
Publication Status
Published